Last reviewed · How we verify
NCT07262138: ACTIVE
Active Surveillance in Older Women With ER+ Breast Cancer
trial testing Active Surveillance in Early Stage Estrogen Receptor (ER) Positive Breast Cancer in 50 participants. Currently enrolling.
1 November 2028
Quick facts
| Lead sponsor | University of Pittsburgh |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 1 November 2025 |
| Primary completion | 1 November 2028 |
| Estimated completion | 31 December 2030 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Active Surveillance
Conditions studied
- Early Stage Estrogen Receptor (ER) Positive Breast Cancer — all drugs for Early Stage Estrogen Receptor (ER) Positive Breast Cancer →
Sponsor
University of Pittsburgh
Who can join
70 and older, female only, with Early Stage Estrogen Receptor (ER) Positive Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
ACTIVE is a prospective, single-arm, phase I/IIa study examining an active surveillance strategy for small, screen-detected, luminal breast cancer. Patients aged 70 or older with clinical stage I ER+/HER2- breast cancer are eligible. The goal of this clinical trial is to learn if an active surveillance strategy (serial imaging rather than therapeutic intervention) is a safe approach to monitor small breast cancers. The main question to answer is the proportion of participants who experience tumor progression by 12 months.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07262138
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Active Surveillance
Trials testing the same drug.
- NCT05345847 — Steroid Sparing in Immune Related Hepatitis (irH) · NA · recruiting
- NCT07023432 — Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE · Phase 2 · not yet recruiting
- NCT06537154 — NEO-BLAST: Neoadjuvant Therapy for Bladder Cancer Followed by Active Surveillance vs Treatment · Phase 2, PHASE3 · recruiting
- NCT06358469 — STRatIfication of Vulvar SCC by HPV and p53 Status to Guide Excision · NA · recruiting
- NCT05840484 — Comprehensive Monitoring of Men With Prostate Cancer Cared for by "Active Surveillance · recruiting
Other University of Pittsburgh trials
Trials by the same sponsor.
- NCT05601206 — Collaborative Care Intervention for Cancer Patients and Their Family Caregivers -LITE · NA · not yet recruiting
- NCT06652815 — Cognition, Metacognition, and Stigma in Patients With Suicidal Ideation · not yet recruiting
- NCT06474286 — Prucalopride for Cognitive Functioning in Schizophrenia · NA · not yet recruiting
- NCT06488469 — Behavioural Problems and Cognition in Children With Hypoglycemia Unawareness in Type-1 Diabetes Mellitus · NA · not yet recruiting
- NCT06652802 — Effectiveness of Nurse-Conducted Brief Intervention (NCBI) Supplemented With Mobile for Preventing Alcohol Use Disorders · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07262138 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Pittsburgh
- Last refreshed: 3 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07262138.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing